Medical/Pharmaceuticals
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China andSHANGHAI, Jan. 10, 2022 /PRNewswire/ -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, IASO Biotherapeutics ("IASO Bio"), a clinical-stage ...
2022-01-11 05:30
3781
Trajan Group acquires Neoteryx LLC
MELBOURNE, Australia, Jan. 10, 2022 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Neoteryx, LLC (Neoteryx), a global leader in blood microsampling devices based inTorrance, California,...
2022-01-11 00:00
3433
CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, today announced thatthe United States Food and Drug Administration (FDA)...
2022-01-10 21:50
4058
SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE
SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...
2022-01-07 23:00
3797
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE
SYDNEY, Jan. 7, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the HC Wainwright BioConnect Conference, to be held virtually from10-13 January 2022. The co...
2022-01-07 21:00
5132
100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients
TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...
2022-01-07 18:53
3094
Li Jian Quan, Chairman of WINNER MEDICAL Co., Ltd., Was Invited to "DIALOGUE PROGRAM" in CCTV-2 (China Central Television)
SHENZHEN, China, Jan. 7, 2022 /PRNewswire/ -- On the evening of January 1, Li Jian quan, chairman of Winner Medical, was a guest on "DIALOGUE PROGRAM" in CCTV-2 (China Central Television) as a representative of entrepreneurs. In the interview, he said that only by insisting on innovation can we b...
2022-01-07 17:47
2574
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development
BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...
2022-01-07 08:30
2820
LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases
SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...
2022-01-06 22:00
2307
I-Mab Announces Senior Management Team Share Purchase Plan
SHANGHAI and GAITHERSBURG, MD., Jan. 6, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the senior management team of the Company, includin...
2022-01-06 21:00
4247
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent ...
2022-01-06 20:30
4198
AKESO'S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH IVONESCIMAB (PD-1/VEGF BI-SPECIFIC ANTIBODY) COMBINED WITH OR WITHOUT CHEMOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE Ib/II CLINICAL TRIAL FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
HONG KONG, Jan. 6, 2022 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Cadonilimab (PD-1/CTLA-4 bi-specific antibody), the first-inclass novel immuno-oncology drug independently developed by the Company, combined with Ivonescimab (PD-1/VEGF bi-specific antibody), the novel immuno-o...
2022-01-06 19:00
2852
Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines
SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...
2022-01-06 14:45
3766
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...
2022-01-06 08:30
8002
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to...
2022-01-06 01:00
2771
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
MINNEAPOLIS, Jan. 5, 2022 /PRNewswire/ -- Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. The purpose of the DeLIVER...
2022-01-05 22:00
2035
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced thatDavid Stamler, M.D., Chief Executive Of...
2022-01-05 20:45
4084
PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech
TOKYO, Jan. 4, 2022 /PRNewswire/ -- PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced it has entered into a multi-target research collaboration and licensing agreement with Roche and Genentech, a member of ...
2022-01-05 09:00
2752
BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics
SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK
Biopharmaceuticals announcedtoday that they have forged a partnership to
research and develop new therapeutic compounds targeting microRNAs [1] (miRNA)
for a potential treatment of epilepsy.
2022-01-05 08:07
2651
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I tri...
2022-01-04 17:28
2636
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 315 media titles]
2026-08-28 09:01Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
[Picked up by 313 media titles]
2026-08-27 10:25
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
[Picked up by 304 media titles]
2026-08-24 10:00
Henox and Nexusguard Announce Strategic Alliance at BATIC 2026 to Power and Protect the Next Generation of Digital Infrastructure
[Picked up by 297 media titles]
2026-08-25 10:00OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
[Picked up by 291 media titles]
2026-08-24 15:42
Most Read
OGA 2026 Positions Kuala Lumpur as the Regional Marketplace for Southeast Asia's Energy Growth
2026-08-24 15:42
19886
AIMX Singapore 2026 Accelerates AI Deployment Through Catalysing Industry Innovation and Advancing Global Collaborations
2026-08-24 10:00
19789
Rewarding Meetings Begin At Hyatt Regency Kuala Lumpur At KL Midtown
2026-08-25 07:00
17741
Klook and Mastercard collaborate to enhance travelers' experiences across Asia Pacific
2026-08-27 10:25
13398